SLC5A2 and type 2 diabetes mellitus: A retrospective study [188] selected a cohort of more than 3 million patients with T2DM divided into five non-overlapping anti-diabetic therapy groups (patients treated with SGLT2-i in association or not with DPP4-I or GLP-1RA; patients treated with GLP-1RA and no previous exposure to other anti-diabetic drugs; patients treated with DPP4-I; other anti-diabetic drugs; no ADD) and concluded that the use of SGLT2-i was not associated with a higher risk of lower-limb complications and no difference was found between the SGLT2-i classes.